click below
click below
Normal Size Small Size show me how
Pharm Autonomic NS
Combined Alph- and Beta-Adrenergic Blockers
| Question | Answer |
|---|---|
| Alpha blockade predominates so they are less likely to cause | significant reductions in HR and CO |
| Two drugs in this category: | carvedilol[Coreg], labetalol[Normodyne] |
| They combine | selective alpha 1 and nonselective beta |
| They decrease BP | standing BP is more affected than supine |
| They decrease myocardial oxygen demand | and lower cardiac workload |
| single dose of labetolol has no effect on | sinus rate, intraventricular conduction or qrs duration |
| no significant effect on serum | lipoproteins |
| Contraindicated in pts with | bronchospastic component, overt NYHA class IV HF, greater than first degree block,and severe bradycardia |
| Coreg has been shown to be effective in class II and III HF b/c of its | limited effects on HR, myocardial contractility, while improving hemodynamics and cardiac performance |
| similar to cautions of BBs in | diabetes and thyroid disease, hepatic impairment |
| risk for orthostatic hypotension higher than with | beta blockers |
| Lab tests affected by labetolol | reversible increase in transaminases, and BUN, false + for amphetamines |
| used to treat essential HTN | alone or in combination with thiazides. dose adjustments based on standing BP |
| use in CHF tx: | Coreg in class II, III HF of ischemic or cardiomyopathy origin inconjunction with diuretics and ACEIs to reduce progression of disease and increase survival [not recommended in all guidelines] |
| labetolol has been use to tx withdrawal HTN associated with | clonidine |
| these drugs must be tapered when discontinued | just like alphas and betas used seperately |
| labetolol may be used when a pt cannot tolerate changes in HR but needs | beta blockade [post MI prophylaxis] |